Osaka, Japan – July 23, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) is pleased to announce that for the first time, it has been selected for the leading ... Read More
STRATEGIC ACQUISITION OF TOSYMRA™ (SUMATRIPTAN) NASAL SPRAY AND ZEMBRACE® SYMTOUCH® (SUMATRIPTAN) INJECTION FURTHER EXPANDS AND DIVERSIFIES COMPANY’S PORTFOLIO
Maple Grove, MN – July 20, 2019 — Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has completed ... Read More
Maple Grove, MN – July 1, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that effective July 1, 2019 it will commercialize the KLOR-CON® (potassium chloride) and Potassium Chloride product families and will continue its ... Read More
Osaka, Japan – June 18, 2019 – Sawai Pharmaceutical Co., Ltd. (Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change application by the Ministry of Health, Labour and Welfare (MHLW) for ... Read More
Osaka, Japan – June 13, 2019 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of three compounds with seven strengths of generic drugs. They will be ... Read More
STRATEGIC ACQUISITION DIVERSIFIES COMPANY’S PORTFOLIO AND PROVIDES NEW OPTIONS FOR MIGRAINE PATIENTS
Maple Grove, MN – June 13, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has agreed to acquire US and other territory ... Read More
Osaka, Japan – June 5, 2019 – Sawai Pharmaceutical Co., Ltd. (Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for ... Read More
Left to right: John Gray (President and CEO of HDA), Mike Muzetras (Senior National Account Manager at Upsher-Smith), Mike McBride (VP Partner Relations at Upsher-Smith), Brad Leonard (Associate VP of National Accounts at Upsher-Smith), Dave ... Read More
